NEW YORK (GenomeWeb) – Nemucore and the Medical Prognosis Institute (MPI) announced today that they have partnered to identify potential responder patients for enrollment in a clinical trial of an undisclosed Nemucore cancer therapeutic.

Under the deal, Nemucore will use MPI's Drug Response Predictor Biomarker platform — which is used to develop tumor-derived gene signatures that may be predictive of how patients respond to certain oncology treatment — to potentially select participants for a planned Phase IIb study of one of its cancer drug candidates.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.